In this context, a selective BRM inhibitor would be lethal to the ca. 10% of non-small-cell lung cancers (NSCLC) where the SMARCA4 gene is lost or mutated, but well tolerated in healthy tissue due to their unaltered expression. Here, SMARCA2 is linked to non-small cell lung carcinoma.